Levels of fibroblastic growth factor 23 (FGF23) in preterm newborns with subclinical phosphate deficiency

  1. Carmen Luz Marrero Pérez 1
  2. Naira Álvarez Martín 1
  3. R. Ruymán Miranda Morales 2
  4. Lorenzo Martín Fumero 2
  5. Carmen Vázquez Moncholi 3
  6. Víctor García Nieto 4
  1. 1 Unidad de Neonatología, Servicio de Pediatría. Hospital Universitario Nuestra Señora de Candelaria
  2. 2 Hospital Universitario Nuestra Señora de Candelaria. Universidad de La Laguna (España)
  3. 3 Servicio de Laboratorio. Hospital Universitario Nuestra Señora de Candelaria
  4. 4 Universidad de La Laguna (España)
Show affiliations +
Journal:
Canarias Pediátrica

ISSN: 1131-6128

Year of publication: 2016

Volume: 40

Issue: 1

Pages: 23-30

Type: Article

DIALNET GOOGLE SCHOLAR lock_openDialnet editor

More publications in: Canarias Pediátrica

Abstract

Objective. To study the calciumphosphorus metabolism and both levels of fibroblast growth factor 23 (FGF23) and intact PTH in preterm newborns with subclinical phosphate deficiency. Patients and methods. A prospective study that included 29 preterm newborns (13 males, 16 females) with a gestational age of between 29 and 36 weeks during the growth phase. We studied several biochemical parameters related to calciumphosphorus metabolism and their levels in diet. Results. Preterm newborns with phosphate deficiency (n=8), also showed hypophosphaturia and hypercalciuria, with a lower growth velocity and reduced levels of both intact PTH and FGF23 related to the control group (n=21). No relation was found between the phosphate content in their diet and the existence of a deficiency of this ion in the body. Only those children who had that deficiency received a lower intake of vitamin D, although the difference was not statistically significant. Conclusions. Newborns with subclinical phosphate deficiency have reduced levels of both phosphaturic hormones in an attempt to preserve the corporal homeostasis of the ion.

Data source: Dialnet